| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Mar 2019 | Mar 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 850K |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.92M | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -1.92M | 0 | 0 | 0 | 0 | 0 | 850K |
| Gross Margin % | - | - | - | - | - | - | 1% |
| Gross Profit Growth % | - | 1% | - | - | - | - | - |
| Operating Expenses | 38.31M | 34.05M | 27.81M | 81.88M | 41.66M | 50.36M | 57.48M |
| OpEx % of Revenue | - | - | - | - | - | - | 67.62% |
| Selling, General & Admin | 11.22M | 11.6M | 12.91M | 10.93M | 11.66M | 12.24M | 15.13M |
| SG&A % of Revenue | - | - | - | - | - | - | 17.8% |
| Research & Development | 27.09M | 22.45M | 14.9M | 20.34M | 30M | 38.12M | 42.34M |
| R&D % of Revenue | - | - | - | - | - | - | 49.81% |
| Other Operating Expenses | 0 | 0 | 0 | 50.62M | 0 | 0 | 0 |
| Operating Income | -38.31M | -34.05M | -27.81M | -81.88M | -41.66M | -50.36M | -56.63M |
| Operating Margin % | - | - | - | - | - | - | -66.62% |
| Operating Income Growth % | - | 0.11% | 0.18% | -1.94% | 0.49% | -0.21% | -0.12% |
| EBITDA | -36.39M | -31.93M | -25.41M | -80.26M | -39.75M | -48.47M | -54.87M |
| EBITDA Margin % | - | - | - | - | - | - | -64.56% |
| EBITDA Growth % | - | 0.12% | 0.2% | -2.16% | 0.5% | -0.22% | -0.13% |
| D&A (Non-Cash Add-back) | 1.92M | 2.12M | 2.4M | 1.62M | 1.9M | 1.89M | 1.75M |
| EBIT | 0 | -34.05M | -27.81M | -81.81M | -41.66M | -50.36M | -56.63M |
| Net Interest Income | -104K | -485K | -820K | -341K | 0 | 0 | 7.3M |
| Interest Income | 663K | 743K | 88K | 29K | 2.36M | 0 | 7.3M |
| Interest Expense | 767K | 1.23M | 908K | 370K | 2.36M | 0 | 0 |
| Other Income/Expense | 233K | -601K | -1.66M | -299K | 2.43M | 7.87M | 7.25M |
| Pretax Income | -38.18M | -34.65M | -29.47M | -82.18M | -39.23M | -42.49M | -49.38M |
| Pretax Margin % | - | - | - | - | - | - | -58.09% |
| Income Tax | 103K | 91K | 32K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -38.29M | -34.74M | -29.5M | -82.18M | -39.23M | -42.49M | -49.38M |
| Net Margin % | - | - | - | - | - | - | -58.09% |
| Net Income Growth % | - | 0.09% | 0.15% | -1.79% | 0.52% | -0.08% | -0.16% |
| Net Income (Continuing) | -38.29M | -34.74M | -29.5M | -82.18M | -39.23M | -42.49M | -49.38M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.66 | -0.67 | -0.52 | -1.31 | -0.35 | -0.33 | -0.36 |
| EPS Growth % | - | 0.91% | 0.22% | -1.52% | 0.73% | 0.06% | -0.09% |
| EPS (Basic) | -7.66 | -0.67 | -0.52 | -1.31 | -0.35 | -0.33 | -0.36 |
| Diluted Shares Outstanding | 5M | 52.11M | 56.22M | 62.87M | 105.19M | 127.03M | 137.11M |
| Basic Shares Outstanding | 5M | 52.11M | 56.22M | 62.87M | 105.19M | 127.03M | 137.11M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Mar 2019 | Mar 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 58.88M | 26.24M | 50.2M | 147.1M | 194.79M | 153.88M | 132.75M |
| Cash & Short-Term Investments | 57.51M | 25.3M | 47.08M | 144.51M | 186.61M | 152.46M | 126.72M |
| Cash Only | 57.51M | 25.3M | 47.08M | 144.51M | 34.95M | 24.23M | 43.48M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 151.66M | 128.23M | 83.24M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.37M | 0 | 0 | 0 | 8.18M | 1.42M | 6.03M |
| Total Non-Current Assets | 5.74M | 4.14M | 1.71M | 6.65M | 4.85M | 2.99M | 7.65M |
| Property, Plant & Equipment | 5.37M | 3.75M | 1.13M | 6.33M | 4.53M | 2.67M | 7.08M |
| Fixed Asset Turnover | - | - | - | - | - | - | 0.12x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 262K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 115K | 392K | 583K | 320K | 320K | 320K | 568K |
| Total Assets | 64.63M | 30.38M | 51.91M | 153.76M | 199.65M | 156.88M | 140.4M |
| Asset Turnover | - | - | - | - | - | - | 0.01x |
| Asset Growth % | - | -0.53% | 0.71% | 1.96% | 0.3% | -0.21% | -0.11% |
| Total Current Liabilities | 8.46M | 9.82M | 10.1M | 10.63M | 16.17M | 7.8M | 8.87M |
| Accounts Payable | 1.73M | 629K | 1.06M | 867K | 3.38M | 4.09M | 2.25M |
| Days Payables Outstanding | 328.71 | - | - | - | - | - | - |
| Short-Term Debt | 3.69M | 5.58M | 7.47M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 519K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.53M | 2.25M | 976K | 1.6M | 1.56M | 1.94M | 2.79M |
| Current Ratio | 6.96x | 2.67x | 4.97x | 13.84x | 12.05x | 19.73x | 14.96x |
| Quick Ratio | 6.96x | 2.67x | 4.97x | 13.84x | 12.05x | 19.73x | 14.96x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 140.93M | 139.16M | 1.87M | 3.05M | 1.84M | 536K | 6.3M |
| Long-Term Debt | 11.06M | 9.29M | 1.87M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 3.05M | 1.84M | 536K | 6.3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 129.87M | 129.87M | 0 | 0 | 0 | 0 | 1K |
| Total Liabilities | 149.4M | 148.98M | 11.97M | 13.68M | 18.01M | 8.34M | 15.17M |
| Total Debt | 14.75M | 14.87M | 9.33M | 4.04M | 2.94M | 1.73M | 6.63M |
| Net Debt | -42.76M | -10.43M | -37.74M | -140.48M | -32.01M | -22.5M | -36.85M |
| Debt / Equity | - | - | 0.23x | 0.03x | 0.02x | 0.01x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -49.95x | -27.73x | -30.63x | -221.30x | -17.65x | - | - |
| Total Equity | -84.77M | -118.6M | 39.95M | 140.08M | 181.64M | 148.54M | 125.23M |
| Equity Growth % | - | -0.4% | 1.34% | 2.51% | 0.3% | -0.18% | -0.16% |
| Book Value per Share | -16.95 | -2.28 | 0.71 | 2.23 | 1.73 | 1.17 | 0.91 |
| Total Shareholders' Equity | -84.77M | -118.6M | 39.95M | 140.08M | 181.64M | 148.54M | 125.23M |
| Common Stock | 2.39M | 1K | 5K | 10K | 13K | 13K | 13K |
| Retained Earnings | -87.16M | -121.91M | -151.41M | -233.59M | -272.81M | -315.31M | -364.68M |
| Treasury Stock | - | - | - | - | - | - | 0 |
| Accumulated OCI | -4.1M | 0 | 0 | 0 | -302K | 37K | 210K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mar 2019 | Mar 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -33.68M | -31.74M | -26.8M | -19.67M | -34.13M | -40.62M | -44.85M |
| Operating CF Margin % | - | - | - | - | - | - | -52.77% |
| Operating CF Growth % | - | 0.06% | 0.16% | 0.27% | -0.74% | -0.19% | -0.1% |
| Net Income | -38.29M | -34.74M | -29.5M | -82.18M | -39.23M | -42.49M | -49.38M |
| Depreciation & Amortization | 1.92M | 2.12M | 2.4M | 1.62M | 1.9M | 1.89M | 1.75M |
| Stock-Based Compensation | 656K | 915K | 4.02M | 4.03M | 5.33M | 6.12M | 8.56M |
| Deferred Taxes | -261K | 109K | 837K | 50.58M | 0 | 0 | 0 |
| Other Non-Cash Items | 121K | 116K | -960K | 41K | -871K | 5.97M | -1.65M |
| Working Capital Changes | 2.17M | -257K | -3.6M | 6.25M | -1.26M | -2.91M | -4.14M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 992K | -1.1M | 432K | -194K | 2.52M | 708K | -1.84M |
| Cash from Investing | -2.02M | -466K | 38K | -1.77M | -151.2M | 26.96M | 46.77M |
| Capital Expenditures | -2.02M | -466K | -106K | -1.57M | -212K | -30K | -44K |
| CapEx % of Revenue | - | - | - | - | - | - | 0.05% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 144 | -318K | -150.99K | 27K | 0 |
| Cash from Financing | 64.03M | 37.63K | 48.54M | 118.61M | 75.76M | 2.94M | 17.34M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 64.03M | 37.63K | -6.32M | -281K | -480K | -159K | -775K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -35.7M | -32.21M | -26.91M | -21.23M | -34.34M | -40.65M | -44.9M |
| FCF Margin % | - | - | - | - | - | - | -52.82% |
| FCF Growth % | - | 0.1% | 0.16% | 0.21% | -0.62% | -0.18% | -0.1% |
| FCF per Share | -7.14 | -0.62 | -0.48 | -0.34 | -0.33 | -0.32 | -0.33 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.91x | 0.91x | 0.24x | 0.87x | 0.96x | 0.91x |
| Interest Paid | - | - | - | - | - | - | 0 |
| Taxes Paid | - | - | - | - | - | - | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -73.85% | -91.3% | -24.38% | -25.74% | -36.07% |
| Return on Invested Capital (ROIC) | - | - | -946.85% | -6808.37% | -41.87% | -27.4% | -39.61% |
| Gross Margin | - | - | - | - | - | - | 100% |
| Net Margin | - | - | - | - | - | - | -5808.82% |
| Debt / Equity | - | - | 0.23x | 0.03x | 0.02x | 0.01x | 0.05x |
| Interest Coverage | -49.95x | -27.73x | -30.63x | -221.30x | -17.65x | - | - |
| FCF Conversion | 0.88x | 0.91x | 0.91x | 0.24x | 0.87x | 0.96x | 0.91x |
Compass Therapeutics, Inc. (CMPX) reported $0.8M in revenue for fiscal year 2024.
Compass Therapeutics, Inc. (CMPX) grew revenue by 0.0% over the past year. Growth has been modest.
Compass Therapeutics, Inc. (CMPX) reported a net loss of $65.8M for fiscal year 2024.
Compass Therapeutics, Inc. (CMPX) has a return on equity (ROE) of -36.1%. Negative ROE indicates the company is unprofitable.
Compass Therapeutics, Inc. (CMPX) had negative free cash flow of $34.2M in fiscal year 2024, likely due to heavy capital investments.